ARAnat Rotstein

Anat Rotstein

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anat Rotstein has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Tasks discriminating cognitive impairment levels: Item Response Theory applied to the Alzheimer's Disease Assessment Scale Cognitive Subscale

    by Anat Rotstein, Stephen Z Levine, Yair Goldberg, Myrto Samara, Kazufumi Yoshida, Andrea Cipriani, Takeshi Iwatsubo, Stefan Leucht, Toshiaki A Furawaka

    Background: Since cognitive impairment is a clinical hallmark of Alzheimer's disease, suitable assessments are essential for treatment and research following onset. The most widely used and researched cognitive impairment measure in clinical trials of Alzheimer's Disease is the Alzheimer's Disease Assessment Scale Cognitive Subscale. Early evidence reported that the measure demonstrated acceptable levels of reliability and validity based on traditional psychometric approaches. Later, more advanced psychometric approaches, such as Item Response Theory, have been implemented to evaluate this measure. Item Response Theory provides details on reliability of different cognitive impairment levels for each item. We aimed to examine tasks discriminating cognitive impairment levels using Item Response Theory based on individual‐level participant clinical trial data. Method: Participants : Individual‐level participant data ( N = 2,198) of five randomized controlled double‐blinded trials of donepezil conducted by Eisai Co. Ltd. Measures: Alzheimer ' s Disease Assessment Scale Cognitive Subscale is a neuropsychological index of cognitive impairment, indicating the severity of cognitive symptoms in Alzheimer's disease. It consists of 11 items to assess memory, language, and praxis functions. Analytic plan : The Graded Response Model, a form of Item Response Theory, was implemented in the 'ltm' package in R. Item discrimination parameters (α) map the ability of an item to discriminate impairment levels. Discrimination parameter values for items ranging from 0.01 to 0.24 are considered very low, 0.25 to 0.64 are low, 0.65 to 1.34 are moderate, 1.35 to 1.69 are high, and over 1.7 are very high. Result: Word recall had the highest ability to discriminate underlying cognitive impairment levels (α=1.92). Four tasks (Spoken language ability, Comprehension of spoken language, Remembering test instruction, and Word finding difficulty) had low item discrimination parameters meaning that these tasks lacked the ability to discriminate underlying cognitive impairment levels. This left seven discriminating tasks (Word recall, Commands, Naming, Constructional praxis, Ideation praxis, Orientation, Word recognition). Conclusion: Seven items separated placebo from donepezil in five pivotal clinical trials of donepezil compared with placebo for Alzheimer's disease. The current study contributes to knowledge on Alzheimer's disease by identifying tasks that discriminate cognitive impairment levels, with potential use for treatment monitoring in moderate‐stage Alzheimer's disease.

  • Open Access

    Sex differences in dementia risk: considering underlying medical conditions

    by Anat Rotstein, Arad Kodesh, Michal Schnaider Beeri, Stephen Z. Levine

    Underlying medical conditions may explain inconsistent reports of the association between sex and dementia risk. The current study aimed to explore the association between sex and the risk of incident dementia, considering a broad range of medical conditions. This prospective national birth cohort study consisted of 53,224 members of a nonprofit health maintenance organization. Participants were born between 1922 and 1946 and entered the cohort on January 1, 2002, aged 55 to 80, without a dementia diagnosis. The cohort was followed up for 18 years to January 1, 2020. Dementia was ascertained based on medical diagnoses. Cox regression models were fitted to quantify the association between sex and the risk of incident dementia with hazard ratios (HR) and their 95% confidence intervals (CI), unadjusted and, in the primary model, adjusted for background demographic factors and 33 medical conditions, classified as ten medical domains. Complementary analyses examined adjustment for each medical domain, and sensitivity analyses provided sex-specific estimates for each demographic or medical domain. The analytic cohort of 53,224 participants had a mean (SD) age at cohort entry of 64.3 (7.08) years (Males: N = 24,489; 46.01%; M=63.47 (6.39); Females: N = 28,735; 53.99%; M=64.35 (6.78)). During follow-up, 8,373 participants (15.73%) were diagnosed with dementia (Females: 17.36%; N = 4,987; Males: 13.83%; N = 3,386). Sex differences in the risk of dementia were null after adjustment for demographic factors and medical conditions (unadjusted HR = 1.08 [95% CI = 1.03–1.13, P = 0.001]; adjusted HR = 1.02 [95% CI, 0.97–1.08; p = 0.38]). Complementary analyses showed that when accounting for some conditions (i.e., circulatory, respiratory, metabolic, digestive, or nervous system diseases; cancer; and injuries), females were at an elevated dementia risk compared to males. However, after accounting for rheumatic and genitourinary diseases, the association between sex and dementia was attenuated to null, and when accounting for psychiatric disorders, males were at greater risk. In this prospective birth cohort, the association between sex and the risk of incident dementia changed when background medical conditions were considered, possibly explaining previous inconsistent reports. Future dementia risk and prevention studies may wish to adequately explore sex differences in medical history.


  • Open Access

    Are women at a higher risk of dementia? A National Study of Underlying Background Medical Conditions

    by Anat Rotstein, Arad Kodesh, Stephen Z Levine

    Background: Studies of the association between sex and the risk of incident dementia are inconsistent, in part conceivably due to sex‐specific background medical conditions.Method: A prospective national cohort study which consisted of 112,204 members of a nonprofit Israeli health maintenance organization born between 1902 and 1952 who entered the cohort on January 1, 2002, without a dementia diagnosis and were followed up to January 1, 2020. Participants were aged 50 to 100 years. Incident dementia was ascertained based on medical diagnoses with International Classification of Diseases codes from the Ninth (331.0‐331.9) and Tenth (F00–F03) revisions. Cox regression models were fitted to quantify the association between sex and the risk of incident dementia with Hazard Ratios (HR) and their 95% Confidence Intervals (CI) unadjusted and adjusted for 34 sources of potential confounding.Results: Women had a higher unadjusted risk for dementia. After adjustment for two demographic factors (birth year and socioeconomic status) and 32 medical conditions (psychiatric disorders, musculoskeletal system, and connective tissue disorders, metabolic syndromes, cardiovascular diseases, respiratory diseases, neurological diseases, genitourinary, digestive, malignant diseases, and injuries) the association between sex and dementia was no longer significant.Conclusion: The commonly reported increased dementia risk for women does not extend once a history of selected medical conditions is considered, suggesting that a more focused outlook on the association between sex and dementia may be a step forward in the identification of at‐risk groups and dementia prevention.

  • Open Access

    Shortening the Alzheimer’s disease assessment scale cognitive subscale

    by Stephen Z. Levine, Yair Goldberg, Anat Rotstein, Myrto Samara, Kazufumi Yoshida, Andrea Cipriani, Takeshi Iwatsubo, Stefan Leucht, Toshiaki A. Furukawa

    Background: A short yet reliable cognitive measure is needed that separates treatment and placebo for treatment trials for Alzheimer’s disease. Hence, we aimed to shorten the Alzheimer’s Disease Assessment Scale Cognitive Subscale (ADAS-Cog) and test its use as an efficacy measure. Methods: Secondary data analysis of participant-level data from five pivotal clinical trials of donepezil compared with placebo for Alzheimer’s disease (N = 2,198). Across all five trials, cognition was appraised using the original 11-item ADAS-Cog. Statistical analysis consisted of sample characterization, item response theory (IRT) to identify an ADAS-Cog short version, and mixed models for repeated-measures analysis to examine the effect sizes of ADAS-Cog change on the original and short versions in the placebo versus donepezil groups. Results: Based on IRT, a short ADAS-Cog was developed with seven items and two response options. The original and short ADAS-Cog correlated at baseline and at weeks 12 and 24 at 0.7. Effect sizes based on mixed modeling showed that the short and original ADAS-Cog separated placebo and donepezil comparably (ADAS-Cog original ES = 0.33, 95% CI = 0.29, 0.40, ADAS-Cog short ES = 0.25, 95% CI =0.23, 0.34). Conclusions: IRT identified a short ADAS-cog version that separated donepezil and placebo, suggesting its clinical potential for assessment and treatment monitoring.


  • Open Access

    Unknown treatment effects of donepezil in Alzheimer’s disease: Network analysis of three double‐blind randomized, placebo‐controlled, clinical trials

    by Anat Rotstein, Stephen Z Levine, Myrto Samara, Kazafumi Yoshida, Yair Goldberg, Andrea Cipriani, Takeshi Iwatsubo, Stefan Leucht, Toshiaki A Furawaka

    Background: Psychometric network analysis is an alternative theoretically‐driven analytic approach that has the potential to conceptualize cognitive impairment in Alzheimer’s disease differently than was previously assumed and consequently detect unknown treatment effects.Method: Based on individual participant data, extracted from three double‐blind, randomized placebo‐controlled clinical trials, psychometric networks were computed on observed Alzheimer’s Disease Assessment Scale Cognitive Subscale scores at baseline (N = 1,554) and on predicted change scores at 24 weeks of follow‐up for participants who received donepezil (N = 797) or placebo (N = 484).Result: A novel conceptualization of cognitive impairment in Alzheimer’s disease was displayed through the baseline network, that had 90% (n = 27) positive statistically significant (p<0.05) associations, and a most central aspect of ideational praxis. Following 24 weeks, treatment effects emerged via the differences between the change networks. The donepezil change network had more statistically significant (p<0.05) positive associations and a higher global strength (n = 15; S = 1.22; p = 0.03), than the placebo network (n = 8; S = 0.57), suggesting that for those who were treated with donepezil cognition is a more unified construct. Less for those given placebo. The main aspects of change in cognitive impairment were comprehension of spoken language for the donepezil network and spoken language ability for the placebo network, suggesting that comprehension of spoken language is most sensitive to pharmaceutical interventions.Conclusion: Overall, psychometric network analysis presents a new conceptualization of cognitive impairment in Alzheimer’s disease, points to previously unknown treatment effects and highlights well‐defined aspects that may translate into future treatment targets.

  • Open Access

    Is cognition integral to psychopathology? A population-based cohort study

    by Anat Rotstein, Suzanne Fund, Stephen Z. Levine, Abraham Reichenberg, Judy Goldenberg

    Background: Lower cognitive functioning has been documented across psychiatric disorders and hypothesized to be a core deficit of mental disorders. Situating psychopathology and cognition as part of a unitary construct is therefore important to understanding the etiology of psychiatric disorders. The current study aims to test competing structural models of psychopathology and cognition in a large national cohort of adolescents.Methods: The analytic sample consisted of 1189 participants aged 16–17 years, screened by the Israeli Draft Board. Psychopathology was assessed using a modified version of the Brief Symptom Inventory, and cognition was assessed based on four standardized test scores ((1) mathematical reasoning, concentration, and concept manipulation; (2) visual-spatial problem-solving skills and nonverbal abstract reasoning; (3) verbal understanding; (4) categorization and verbal abstraction). Confirmatory factor analysis was implemented to compare competing structural models of psychopathology with and without cognition. Sensitivity analyses examined the models in different subpopulations.Results: Confirmatory factor analysis indicated a better model fit of psychopathological symptoms without cognition (RMSEA = 0.037; TLI = 0.991; CFI = 0.992) than with cognition (RMSEA = 0.04–0.042; TLI = 0.987–0.988; CFI = 0.988–0.989). Sensitivity analyses supported the robustness of these results with a single exception. Among participants with low cognitive abilities (N= 139), models that integrated psychopathological symptoms with cognition had a better fit compared to models of psychopathology without cognition.Conclusions: The current study suggests that cognition and psychopathology are, generally, independent constructs. However, within low cognitive abilities, cognition was integral to the structure of psychopathology. Our results point toward an increased vulnerability to psychopathology in individuals with low cognitive abilities and may provide valuable information for clinicians.


  • Open Access

    Serum folate deficiency and the risks of dementia and all-cause mortality: a national study of old age

    by Anat Rotstein, Arad Kodesh, Yair Goldberg, Abraham Reichenberg, Stephen Z Levine

    Background The association between serum folate deficiency and the risk of dementia in old age is unclear, perhaps owing to small sample sizes, the competing risk of mortality or reverse causation. Objective To examine the associations between serum folate deficiency and the risks of incident dementia and all-cause mortality in a large national sample of older adults. Methods A prospective cohort aged 60–75 years (n=27 188) without pre-existing dementia for at least 10 years, was tested for serum concentrations of folate and followed up for dementia or all-cause mortality. Serum folate deficiency was classified as present (Findings The presence compared with the absence of serum folate deficiency was associated with higher risks of dementia (HR=1.68; 95% CI 1.32 to 2.13; pConclusions Serum concentrations of folate may function as a biomarker used to identify those at risk of dementia and mortality; however, reverse causation is likely. Further research is needed to examine the role of serum folate deficiency in dementia aetiology. Clinical implications Serum folate deficiency in older adults requires monitoring and treatment for preventative measures and/or as part of implemented therapeutic strategies.


  • Open Access

    Gender differences in quality of life and the course of schizophrenia: national study

    by Anat Rotstein, Efrat Shadmi, David Roe, Marc Gelkopf, Stephen Z. Levine

    Background Evidence from various sources suggests that females with schizophrenia tend to report lower quality of life than males with schizophrenia despite having a less severe course of the disorder. However, studies have not examined this directly. Aims To examine gender differences in the association between quality of life and the risk of subsequent psychiatric hospital admissions in a national sample with schizophrenia. Method The sample consisted of 989 (60.90%) males and 635 (39.10%) females with an ICD-10 diagnosis of schizophrenia. Quality of life was assessed and scored using the Manchester Short Assessment of Quality of Life. The course of schizophrenia was assessed from the number of psychiatric hospital admissions. Participants completed the quality of life assessment and were then followed up for 18-months for subsequent psychiatric admissions. Hazard ratios (HR) from Cox proportional hazards regression models were estimated unadjusted and adjusted for covariates (age at schizophrenia onset and birth year). Analyses were computed for males and females separately, as well as for the entire cohort. Results A subsample of 93 males and 55 females was admitted to a psychiatric hospital during follow-up. Higher quality of life scores were significantly (P < 0.05) associated with a reduced risk of subsequent admissions among males (unadjusted: HR = 0.96, 95% CI 0.93–0.99; adjusted HR = 0.96, 95% CI 0.93–0.99) but not among females (unadjusted: HR = 0.97, 95% CI 0.93–1.02; adjusted HR = 0.97, 95% CI 0.93–1.02). Conclusions Quality of life in schizophrenia is a gender-specific construct and should be considered as such in clinical practice and future research.